EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | --- | | 股票發行人現金股息公告 | | | | 發行人名稱 | 上海昊海生物科技股份有限公司 | | | 股份代號 | 06826 | | | 多櫃檯股份代號及貨幣 | 不適用 | | | 相關股份代號及名稱 | 不適用 | | | 公告標題 | 截至2025年6月30日止六個月期間之中期業績公告 | | | 公告日期 | 2025年8月22日 | | | 公告狀態 | 新公告 | | | 股息信息 | | | | 股息類型 | 中期（半年期） | | | 股息性質 | 普通股息 | | | 財政年末 | 2025年12月31日 | | | 宣派股息的報告期末 | 2025年6月30日 | | | 宣派股息 | 每 股 0.4 RMB | | | 股東批准日期 | 不適用 | | | 香港過戶登記處相關信息 | | | | 派息金額及 ...

Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, attributed to external market challenges and regulatory changes affecting product pricing and demand [1][2]. Financial Performance - The company recorded a total revenue of approximately RMB 1.293 billion, a year-on-year decrease of about 7.48% [1]. - Research and development expenses amounted to approximately RMB 98.4 million, down about 21.53% year-on-year, representing 7.61% of total revenue [1]. - Profit attributable to ordinary shareholders was approximately RMB 211 million, a decline of about 10.29% year-on-year, with basic earnings per share at RMB 0.91 [1]. Business Segments - The company focuses on four core business segments: medical aesthetics, ophthalmology, orthopedics, and anti-adhesion & hemostasis, and has been actively responding to market opportunities and challenges [2]. - Revenue from the ophthalmology product line decreased by approximately RMB 83.51 million, a decline of about 18.57% compared to the same period in 2024, influenced by national procurement policies and a sluggish domestic consumption market [2]. - Revenue from the medical aesthetics and wound care product line fell by approximately RMB 58.55 million, a decrease of about 9.27%, primarily due to reduced domestic demand for the first and second generation hyaluronic acid products [2]. Product Innovations and Market Developments - The anti-adhesion and hemostasis product line saw revenue growth of approximately RMB 41.1 million, an increase of about 59.68%, mainly due to the inclusion of the "Kangrui Gel" product in the Shanghai biopharmaceutical "New and Excellent Drug and Device" product directory [3]. - The inclusion in the directory allows the product to access a green channel for public hospital admission in Shanghai and prioritize recommendations for Shanghai medical insurance negotiations, enhancing market access and patient willingness to pay [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 為釐定有權獲得中期股息的H股股東名單，本公司將於2025年9月9日（星期二）至 2025年9月12日（星期五）止（包括首尾兩天）期間暫停辦理股份過戶登記手續，該 期間將不辦理H股過戶手續。凡於2025年9月12日（星期五）名列本公司股東名冊 的H股股東均有權收取中期股息。為接獲中期股息，尚未登記其過戶的H股股東應 於2025年9月8日（星期一）下午4:30或之前，將過戶文件連同相關股票送呈至H股 證券登記處，其地址為香港灣仔皇后大道東183號合和中心17樓1712-1716號舖。 茲提述上海昊海生物科技股份有限公司（「本公司」）日期為2025年5月9日的2024 年度股東周年大會（「股東周年大會」）通函（「通函」）及日期為2025年6月10日的公 告，內容有關（其中包括）本公司 ...

Financial Performance - The company recorded revenue of approximately RMB 1,292.64 million for the six months ended June 30, 2025, a decrease of about RMB 104.47 million or 7.48% compared to RMB 1,397.11 million in the same period of 2024[2]. - Profit attributable to equity holders of the company was approximately RMB 211.07 million, a decline of 10.29% from RMB 235.28 million in the same period of 2024[2][6]. - Basic earnings per share for the period were RMB 0.91, compared to RMB 1.01 in 2024[2][6]. - Gross profit for the period was RMB 906.28 million, down from RMB 983.30 million in 2024, reflecting a decrease in gross margin[4]. - Total comprehensive income for the period was RMB 251.81 million, compared to RMB 196.74 million in 2024, indicating an increase in overall profitability[6]. - The group's profit before tax for the six months ended June 30, 2025, was RMB 211,065,000, a decrease of 10.3% compared to RMB 235,283,000 for the same period in 2024[33]. - The total tax expense for the period was RMB 33,965,000, a decrease of 24.4% compared to RMB 44,834,000 for the same period in 2024[28]. - The overall gross profit margin for the reporting period was 70.11%, remaining stable compared to 70.38% in the same period of 2024[82]. Research and Development - Research and development expenses amounted to approximately RMB 98.40 million, down by RMB 27.00 million or 21.53% from RMB 125.40 million in 2024, representing 7.61% of revenue[2][4]. - The company received government subsidies amounting to RMB 7,907,000 for R&D activities, an increase from RMB 6,963,000 in 2024[23]. - Research and development costs for the six months ended June 30, 2025, were RMB 98,401,000, down 21.5% from RMB 125,400,000 in 2024[24]. - The group has several key R&D projects progressing, including the registration phase for multiple new products expected to enhance future revenue streams[46]. - The group will promote high-end hyaluronic acid products and continue clinical trials for important R&D projects, including painless cross-linked hyaluronic acid[77]. Assets and Liabilities - Non-current assets totaled RMB 3,483.08 million as of June 30, 2025, slightly up from RMB 3,463.12 million at the end of 2024[7]. - Current assets increased to RMB 3,702.72 million from RMB 3,658.27 million at the end of 2024, driven by higher trade receivables and cash balances[8]. - The company's total equity was RMB 5,882.26 million, a slight decrease from RMB 5,917.04 million at the end of 2024[8]. - The total liabilities as of June 30, 2025, were approximately RMB 1,303.54 million, with a debt-to-asset ratio of 18.14%, an increase of 1.23 percentage points from 16.91% on December 31, 2024[92]. - Cash and cash equivalents as of June 30, 2025, were approximately RMB 614.29 million, a decrease of about RMB 498.62 million compared to RMB 1,112.91 million on December 31, 2024[93]. Share Repurchase and Dividends - The company repurchased a total of 12,938,800 H-shares from March 2020 to December 2024, with 12,742,900 shares canceled by December 31, 2024[10]. - For A-shares, the company completed the first round of repurchases totaling 2,015,674 shares from August 2023 to August 2024, followed by a second round of 1,832,421 shares from November 2024 to June 2025[11]. - The board declared an interim dividend of RMB 0.40 per share (tax inclusive), unchanged from the same period in 2024[2]. - The board approved an interim dividend of RMB 0.40 per share (tax included), amounting to a total of RMB 91,493,200.00 (tax included) based on 232,581,095 shares issued[103]. Market Performance - Revenue from customer contracts for the six months ended June 30, 2025, was RMB 1,292,636,000, a decrease of 7.5% compared to RMB 1,397,112,000 for the same period in 2024[19]. - Revenue from medical beauty and wound care products was RMB 573,270,000, down from RMB 631,817,000 in 2024, representing a decline of 9.2%[19]. - Revenue from ophthalmic products decreased to RMB 366,148,000 from RMB 449,659,000, a decline of 18.5%[19]. - The company's product lines showed varied performance, with the ophthalmic products segment declining by 18.57% year-on-year[44]. - The medical beauty market is shifting from rapid expansion to a focus on quality and value, amidst challenges such as regulatory tightening and slowing growth of end institutions[50]. Regulatory and Compliance - The company has complied with all applicable provisions of the Corporate Governance Code under the Hong Kong Listing Rules[104]. - The company has adopted the standard code of conduct for securities trading by directors and supervisors, confirming compliance during the reporting period[105]. - The audit committee held four meetings during the reporting period to review financial statements and internal controls[106]. Future Outlook - The group plans to continue focusing on the four rapidly developing treatment areas: medical beauty, ophthalmology, orthopedics, and surgery, while enhancing research and development and operational efficiency[75]. - The group aims to integrate acquired companies effectively to maximize synergy, improve operational efficiency, and enhance core competitiveness by the second half of 2025[76]. - The group anticipates multiple high-end products, including hydrophobic non-spherical artificial lenses, to be approved within the year, enhancing the overall product line[78].

Core Viewpoint - The domestic medical beauty industry is undergoing significant changes, with major players experiencing a decline in performance due to market shifts and increased competition from new regenerative materials like collagen and "童颜针" (youthful needle) [4][7][14]. Group 1: Industry Performance - The three major companies in the medical beauty sector, including 华熙生物, 爱美客, and 昊海生科, reported substantial declines in revenue and net profit, with 爱美客's revenue dropping by 21.59% to 12.99 billion yuan and net profit decreasing by 29.57% to 7.89 billion yuan in the first half of 2024 [7][8]. - 爱美客's core products, including "嗨体" and "濡白天使," saw revenue declines of 23.79% and 23.99%, respectively, despite maintaining high gross margins of over 90% [6][7]. Group 2: Market Trends - The introduction of "童颜针," particularly the imported product 艾塑菲, has gained rapid popularity, with sales reaching 20,000 units and contributing over 800 million yuan in revenue within two months of its launch [5][17]. - The shift towards regenerative materials is evident, as "童颜针" offers longer-lasting effects and a different mechanism compared to traditional hyaluronic acid fillers, which are facing price declines due to increased competition [16][17]. Group 3: Strategic Moves - 爱美客's acquisition of REGEN, a Korean medical beauty company, for 1.386 billion yuan marks the largest cross-border acquisition in the domestic medical beauty industry, aiming to enhance its product portfolio and market presence [5][9]. - The ongoing dispute between 江苏吴中 and 爱美客 over the distribution rights of 艾塑菲 highlights the competitive landscape and the challenges of dependency on agency models in the medical beauty sector [19][20]. Group 4: R&D and Innovation - 爱美客 has increased its R&D investment to 1.57 billion yuan, representing 12.05% of its revenue, indicating a focus on enhancing its competitive edge through innovation [8]. - The company holds 182 valid patents, including 53 invention patents, showcasing its commitment to developing proprietary technologies [8].

第二条 本制度所称"内部审计"，是公司内部独立、客观的保证与咨询活 动，它通过系统化、规范化的方法，评价、改进公司和下属单位等组织机构、人 员及其经营管理行为在风险管理、内部控制和公司治理过程中的效果，帮助公司 实现其目标。 本制度所称"审计人员"，是指在公司和下属单位从事审计工作的人员，包 括审计部专职审计人员、非专职的审计人员。 本制度所称"下属单位"，是指公司各职能部门和下属全资子公司、控股子 公司和具有重大影响的参股公司。 第三条 公司实行内部审计制度。 上海昊海生物科技股份有限公司 内部审计制度 上海昊海生物科技股份有限公司 内部审计制度 第一章 总则 第一条 为规范上海昊海生物科技股份有限公司（以下简称"公司"）内部 审计工作，明确内部审计的职责和权限，发挥内部审计在强化内部控制、改善经 营管理、提高经济效益中的作用，促进公司经营效率、经济效益的提高，确保内 部控制持续有效实施，维护投资者的权益，实现内部审计的制度化和规范化，根 据《中华人民共和国审计法》《审计署关于内部审计工作的规定》《中国内部审 计准则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 及其他相关法律和法规， ...

上海昊海生物科技股份有限公司 信息披露事务管理制度 上海昊海生物科技股份有限公司 第二章 信息披露基本原则 第三条 公司及其他信息披露义务人应当及时依法履行信息披露义务，披露的 信息应当真实、准确、完整，简明清晰、通俗易懂，以客观事实或者具有事实基 础的判断和意见为依据，不得有虚假记载、误导性陈述、夸大其辞或者因重大遗 漏而属虚假或具误导性，应当揭示可能产生的重大风险。 公司及其他信息披露义务人应当在境外市场和境内市场同时向所有投资者公 开披露信息，不得提前向任何单位和个人泄露。但是，法律、法规另有规定的除 外。 信息披露事务管理制度 第一章 总则 第一条 为规范上海昊海生物科技股份有限公司（以下简称"公司"）的信息披 露行为，加强公司信息披露事务管理，促进公司依法规范运作，维护公司股东的合法 权益，根据《中华人民共和国公司法》《中华人民共和国证券法》（以下简称"《证 券法》"）、中国证券监督管理委员会（以下简称"中国证监会"）《上市公司信息 披露管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板股票上市 规则》（以下简称"《科创板上市规则》"）、《香港联合交易所有限公司证券上市 规则》 （以下简 ...

Core Viewpoint - The document outlines the management measures for the shareholding changes of directors and senior management at Shanghai Haohai Biological Technology Co., Ltd, emphasizing compliance with various laws and regulations regarding insider trading and share transactions. Group 1: General Provisions - The management measures are established to regulate the shareholding of directors and senior management in accordance with the Company Law, Securities Law, and other relevant regulations [1][2]. - Directors and senior management are prohibited from engaging in margin trading or derivative transactions involving the company's shares [2]. Group 2: Information Reporting - Directors and senior management must report their shareholding information to the company secretary within specified timeframes, including changes in personal information and share transactions [5][6]. - The company secretary is responsible for managing and reporting the shareholding data of directors and senior management [4]. Group 3: Notification Requirements - Directors and senior management must notify the chairman or a designated director in writing before buying or selling company shares, and must receive confirmation before proceeding with the transaction [6][7]. - Any changes in shareholding must be reported to the board secretary within two trading days [7]. Group 4: Restrictions on Share Transfers - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or within six months after leaving the company [9][10]. - Specific periods are defined during which directors and senior management cannot trade company shares, particularly around the announcement of financial reports [9]. Group 5: Transfer Regulations - Directors and senior management can only transfer up to 25% of their total shareholding within a specified timeframe after their appointment [14]. - If the number of shares held is less than 1,000, they may transfer all shares without restriction [15]. Group 6: Special Provisions for Share Reduction - A reduction plan must be reported to the stock exchange 15 trading days prior to the first sale, detailing the number of shares, reasons for reduction, and compliance with regulations [21][22]. - Any significant corporate events must be disclosed alongside the progress of share reductions [22]. Group 7: Legal Responsibilities - Directors and senior management are liable for any violations of these management measures, and any illegal gains from such violations must be returned to the company [24][25].

证券代码：688366 证券简称：昊海生科 公告编号：2025-039 上海昊海生物科技股份有限公司 2025 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 每股分配比例：每 10 股派发现金红利人民币 4.00 元（含税）。不送红 股，不进行资本公积金转增股本。 ● 本次利润分配以实施权益分派股权登记日登记的总股本扣除上海昊海生 物科技股份有限公司（以下简称"公司"）回购专用证券账户中股份为基数，具 体日期将在权益分派实施公告中明确。 ● 在实施权益分派的股权登记日前公司应分配股数（总股本扣除公司回购 专用证券账户股份余额）发生变动的，拟维持每股分配的股息比例不变，相应调 整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 公司 2025 年半年度中国会计准则及国际财务报告准则合并财务报表归属于 母公司股东的净利润均为人民币 211,065,253.90 元，母公司净利润均为人民币 94,275,068.13 元。截至 2025 年 6 月 30 日，公司母公司报 ...

上海昊海生物科技股份有限公司2025 年半年度报告 上海昊海生物科技股份有限公司2025 年半年度报告 公司代码：688366 公司简称：昊海生科 上海昊海生物科技股份有限公司 2025 年半年度报告 1 / 180 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 敬请参阅本报告"第三节 管理层讨论与分析"之"四、风险因素"相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人侯永泰、主管会计工作负责人唐敏捷及会计机构负责人（会计主管人员）卞亦 平声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟以实施权益分派股权登记日登记的总股本扣除公司回购专用证券账户中股份为基数， 向全体股东每 10 股派发现金红利人民币 4.00 元（含税）。截至本报告披露日，公司总股本为 232,581,095 股，扣除回购专用证券账户中股份数 3,848,095 股（全部为 A 股股份）， ...